Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Intrahepatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

No.2 People's Hospital of Fuyang city, Fuyang, Anhui, China
Contact: Study coordinator (DaYong Luo) · fyldy7172@sina.com · 13805587172
Anhui province hospital, Hefei, Anhui, China
Contact: Study coordinator (Ji-Zhou Wang, M.D.) · wangjoe@ustc.edu.cn · +86 13836135864

Study leads

Lian-xin Liu
Principal Investigator
Anhui Provincial Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)Recruiting

Beijing, China

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Fairfax, United States

A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Bile Duct Cancer · Cholangiocarcinoma · Cholangiocarcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE2

Boston, United States